[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Os Therapies Incorporated (OSTX)

Os Therapies Incorporated (OSTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 76,605
  • Shares Outstanding, K 44,538
  • Annual Sales, $ 0 K
  • Annual Income, $ -28,750 K
  • EBIT $ -34 M
  • EBITDA $ -32 M
  • 60-Month Beta -0.95
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 1
  • High Estimate $-0.23
  • Low Estimate $-0.23
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) -21.05%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.6250 +18.77%
on 06/16/26
2.1986 -12.22%
on 06/01/26
+0.2000 (+11.56%)
since 05/18/26
3-Month
1.1600 +66.38%
on 04/07/26
2.1986 -12.22%
on 06/01/26
+0.4200 (+27.81%)
since 03/18/26
52-Week
1.1500 +67.83%
on 02/19/26
2.5700 -24.90%
on 08/22/25
+0.1100 (+6.04%)
since 06/18/25

Most Recent Stories

More News
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma

Confirmatory Phase 3 trial to commence prior to BLA grant under Accelerated Approval Program in the U.S. and Conditional MAA in the U.K., Europe and AustraliaPatent pending pharmacodynamic response biomarker...

OSTX : 1.9300 (+12.21%)
OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma

75% 2.5-year overall survival for OST-HER2 vs. 47% pooled historical control (p = 0.003), with no new patient deaths reported since the 2-year overall survival data (75% vs. 60%, p = 0.034)Updated clinical...

OSTX : 1.9300 (+12.21%)
OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World

The Company confirms that it will release 2.5 year overall survival data from Phase 2b clinical trial OST-HER2 in the prevention or delay of recurrence in fully-resected pulmonary metastatic osteosarcoma...

OSTX : 1.9300 (+12.21%)
OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences

ASCO 2026: 2.5-Year Overall Survival DataJefferies Healthcare Conference: Partnering & Investor meetingsBIO International Convention: Panel ParticipationMIB Agents Factor Osteosarcoma Conference: Data...

OSTX : 1.9300 (+12.21%)
OS Therapies Reports First Quarter 2026 Financials and Provides Business Update

$5.5 million financing that closed on April 2, 2026 together with $5.7 million in capital raised in Q1-2026, expected to provide Company with cash runway into 2027$4.5 million of accrued VAT refunds and...

OSTX : 1.9300 (+12.21%)
OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026

New York, New York and Rockville, Maryland--(Newsfile Corp. - May 15, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, listeria-based...

OSTX : 1.9300 (+12.21%)
OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor

Appointment strengthens medical, regulatory, and commercial leadership as Company prepares to complete early market access regulatory filings in the U.S., U.K, Europe and Australia in anticipation of OST-HER2...

OSTX : 1.9300 (+12.21%)
OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma

Conference call scheduled for Thursday, April 30, 2026, at 8:30 am ET to review new OST-HER2 immune pharmacodynamic biomarker response (seroconversion) data and review regulatory successes validating the...

OSTX : 1.9300 (+12.21%)
OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET

Regulatory feedback recent from April 2026 EU EMA and Australian TGA meetingsRemaining Q2-2026 regulatory meetings include two U.S. FDA meetings and one UK MHRA meeting, in addition to follow-up meetings...

OSTX : 1.9300 (+12.21%)
OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes

New patent application covers treatment-emergent immune signature related to 'turning cold tumors hot' and the activation of targeted cytotoxic cellular immune responses Company to host conference call...

OSTX : 1.9300 (+12.21%)

Business Summary

OS Therapies Incorporated is a clinical stage oncology company focused on the identification, development and commercialization of treatments for Osteosarcoma and other solid tumors. The company's lead asset consists OST-HER2. OS Therapies Incorporated is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 2.2400
2nd Resistance Point 2.1000
1st Resistance Point 2.0150
Last Price 1.9300
1st Support Level 1.7900
2nd Support Level 1.6500
3rd Support Level 1.5650

See More

52-Week High 2.5700
Fibonacci 61.8% 2.0276
Last Price 1.9300
Fibonacci 50% 1.8600
Fibonacci 38.2% 1.6924
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.